Building on a record year of Chromium product releases in 2024, 10x Genomics announced plans to enable high-performance, mega ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.

Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...

Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered ...

Stifel lowered the firm’s price target on 10x Genomics (TXG) to $18 from $21 and keeps a Buy rating on the shares. The funding environment ...

Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq ... archived and available for replay for at least 45 days after the event.

At this time, I would like to welcome everyone to the 10X Genomics fourth quarter and full year 2024 earnings conference call. (Operator Instructions). I would now like to turn the conference over to ...

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will ...